bioRxivMicrobiology
SARS-CoV-2 Spreads through Cell-to-Cell Transmission
C. Zeng, J. P. Evans, T. King, Y.-M. Zheng, E. M. Oltz, S. P. J. Whelan, L. Saif, M. E. Peeples, S.-L. Liu
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible coronavirus responsible for the global COVID-19 pandemic. Herein we provide evidence that SARS-CoV-2 spreads through cell-cell contact in cultures, mediated by the spike glycoprotein. SARS-CoV-2 spike is more efficient in facilitating cell-to-cell transmission than SARS-CoV spike, which reflects, in part, their differential cell-cell fusion activity. Interestingly, treatment of cocultured cells with endosomal entry inhibitors impairs cell-to-cell transmission, implicating endosomal membrane fusion as an underlying mechanism. Compared with cell-free infection, cell-to-cell transmission of SARS-CoV-2 is refractory to inhibition by neutralizing antibody or convalescent sera of COVID-19 patients. While ACE2 enhances cell-to-cell transmission, we find that it is not absolutely required. Notably, despite differences in cell-free infectivity, the variants of concern (VOC) B.1.1.7 and B.1.351 have similar cell-to-cell transmission capability. Moreover, B.1.351 is more resistant to neutralization by vaccinee sera in cell-free infection, whereas B.1.1.7 is more resistant to inhibition by vaccine sera in cell-to-cell transmission. Overall, our study reveals critical features of SARS-CoV-2 spike-mediated cell-to-cell transmission, with important implications for a better understanding of SARS-CoV-2 spread and pathogenesis.
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralization
L. Jackson, H. Rodel, … A. Sigal·bioRxiv·Jun 1, 2021
- Post-entry, spike-dependent replication advantage of B.1.1.7 and B.1.617.2 over B.1 SARS-CoV-2 in an ACE2-deficient human lung cell line
D. Niemeyer, S. Schroeder, … C. Drosten·bioRxiv·Oct 20, 2021
- The anti-HIV Drug Nelfinavir Mesylate (Viracept) is a Potent Inhibitor of Cell Fusion Caused by the SARS-CoV-2 Spike (S) Glycoprotein Warranting further Evaluation as an Antiviral against COVID-19 infections
F. Musarrat, V. Chouljenko, … K. Kousoulas·bioRxiv·Apr 24, 2020
- SARS-CoV-2 cell-to-cell infection is resistant to neutralizing antibodies
N. Kruglova, A. E. Siniavin, … D. Mazurov·bioRxiv·May 4, 2021
- SARS-CoV-2 and SARS-CoV spike-mediated cell-cell fusion differ in the requirements for receptor expression and proteolytic activation
B. F. Hörnich, A. K. Grosskopf, … A. S. Hahn·Journal of VirologyPeer-reviewed·Apr 12, 2021
- Deletion of the Envelope gene attenuates SARS-CoV-2 infection by altered Spike localization and increased cell-to-cell transmission
Hannah L. Fischer, Shanmugapriya Shanmugapriya, … Zandrea Ambrose·bioRxiv·May 20, 2025